Cardizem CD settlement
Executive Summary
Andrx and Aventis will pay $80 mil. to settle Cardizem CD antitrust litigation brought by indirect purchaser class of plaintiffs and 50 state attorneys general plus the District of Columbia and Puerto Rico. Settlement is subject to approval by Detroit federal court. Andrx' portion is covered by $60 mil. litigation charge reported in second quarter 2002, company says (1"The Pink Sheet" July 15, 2002, p. 7). In March 2001, FTC entered into a consent order with Aventis and Andrx after the commission alleged that Abbott paid Andrx not to enter the market while Cardizem CD (diltiazem)litigation was pending (2"The Pink Sheet" April 9, 2001, p. 4)...
You may also be interested in...
Naprelan Generic Exclusivity Settled; Andrx Sees Three Near-Term Launches
SkyePharma has waived its 180-day exclusivity for a generic version of Elan's Naprelan (naproxen), clearing the way for approval of Andrx' generic version of the product, Andrx says
Andrx/Aventis Settle With FTC: Agency Says Cardizem CD Generic Not Delayed
Aventis and Andrx' consent agreement with the Federal Trade Commission includes an acknowledgement by the agency that the patent litigation settlement between the two companies did not delay the advent of generic competition to Cardizem CD.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.